Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$66.15
+1.3%
$63.56
$52.50
$77.00
$1.43B0.57314,151 shs191,074 shs
Biohaven Ltd. stock logo
BHVN
Biohaven
$14.82
+2.3%
$16.26
$13.75
$55.70
$1.51B0.911.30 million shs933,333 shs
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$2.84
+3.5%
$2.27
$0.87
$4.08
$393.41M1.48971,125 shs732,658 shs
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$25.40
-0.4%
$24.90
$22.48
$71.71
$1.50B2.86867,100 shs346,846 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
+0.37%+0.14%+3.37%+0.29%+6.47%
Biohaven Ltd. stock logo
BHVN
Biohaven
+3.96%-2.17%-15.38%-15.46%-58.98%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
+3.40%+4.58%+6.61%+66.06%+216.40%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
+4.25%+5.94%-1.73%-5.14%-38.81%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.4065 of 5 stars
2.51.00.03.30.63.31.3
Biohaven Ltd. stock logo
BHVN
Biohaven
3.1739 of 5 stars
4.51.00.00.01.82.50.6
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
2.4536 of 5 stars
3.62.00.00.00.05.00.0
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
1.5412 of 5 stars
3.51.00.00.00.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.00
Buy$78.8819.25% Upside
Biohaven Ltd. stock logo
BHVN
Biohaven
3.07
Buy$58.46294.61% Upside
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3.10
Buy$12.67346.80% Upside
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3.09
Buy$95.25275.06% Upside

Current Analyst Ratings Breakdown

Latest CMPX, JANX, BHVN, and ANIP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$84.00
7/1/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform$9.00
6/18/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$68.00 ➝ $55.00
5/19/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.00
5/13/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/13/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$61.00 ➝ $54.00
5/12/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$86.00 ➝ $86.00
5/9/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
4/28/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$60.00 ➝ $57.00
4/28/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/24/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$614.38M2.33$7.73 per share8.56$19.11 per share3.46
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/A$4.19 per shareN/A
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$850K461.20N/AN/A$0.91 per share3.12
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$10.59M141.90N/AN/A$19.49 per share1.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-$18.52M-$1.27N/A15.71N/A-3.12%21.35%7.52%8/5/2025 (Estimated)
Biohaven Ltd. stock logo
BHVN
Biohaven
-$846.42M-$9.36N/AN/AN/AN/A-257.07%-164.01%8/5/2025 (Estimated)
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$49.38M-$0.41N/AN/AN/AN/A-42.47%-38.31%8/11/2025 (Estimated)
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$68.99M-$1.36N/AN/AN/AN/A-9.29%-8.89%8/6/2025 (Estimated)

Latest CMPX, JANX, BHVN, and ANIP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$0.50N/AN/AN/A$0.30 millionN/A
8/5/2025Q2 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.49N/AN/AN/A$187.18 millionN/A
5/12/2025Q1 2025
Biohaven Ltd. stock logo
BHVN
Biohaven
-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A
5/9/2025Q1 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.37$1.70+$0.33$0.69$179.75 million$197.12 million
5/8/2025Q1 2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$0.12-$0.12N/A-$0.12N/AN/A
5/8/2025Q1 2025
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
N/AN/AN/AN/AN/A
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/AN/A
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/AN/AN/AN/AN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
1.46
2.66
1.98
Biohaven Ltd. stock logo
BHVN
Biohaven
N/A
2.33
2.33
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/A
8.33
8.33
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/A
58.47
58.47

Institutional Ownership

CompanyInstitutional Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
76.05%
Biohaven Ltd. stock logo
BHVN
Biohaven
88.78%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
68.43%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
75.39%

Insider Ownership

CompanyInsider Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
11.10%
Biohaven Ltd. stock logo
BHVN
Biohaven
16.00%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
29.80%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
8.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
60021.66 million19.26 millionOptionable
Biohaven Ltd. stock logo
BHVN
Biohaven
239102.11 million85.78 millionOptionable
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
20138.28 million97.08 millionNot Optionable
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
3059.17 million54.38 millionOptionable

Recent News About These Companies

Janux Therapeutics Becomes Oversold (JANX)
Janux Therapeutics: What's My Inflection Point?
Janux Therapeutics: What's My Inflection Point?

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANI Pharmaceuticals stock logo

ANI Pharmaceuticals NASDAQ:ANIP

$66.14 +0.84 (+1.28%)
As of 03:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Biohaven stock logo

Biohaven NYSE:BHVN

$14.82 +0.34 (+2.31%)
As of 03:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Compass Therapeutics stock logo

Compass Therapeutics NASDAQ:CMPX

$2.84 +0.10 (+3.47%)
As of 03:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Janux Therapeutics stock logo

Janux Therapeutics NASDAQ:JANX

$25.40 -0.09 (-0.37%)
As of 03:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.